Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Phase 1/2 Completed 23 enrolled University of Washington National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial is studying the side effects of escalating doses of adoptive T cell therapy in treating patients with stage IV breast cancer. Vaccines are given to patient prior the expansion of a person's white blood cells may help the body build an effective immune response to kill tumor cells that overexpress human epidermal growth factor receptor 2 (HER2)

Timeline

Start: 2008-10
Primary completion: 2013-07
Completion: 2014-12

Publications

Stanton SE, Eary JF, Marzbani EA, Mankoff D, Salazar LG, Higgins D, Childs J, Reichow J, Dang Y, Disis ML. Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo. J Immunother Cancer. 2016 May 17;4:27. doi: 10.1186/s40425-016-0131-3. eCollection 2016.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HER-2/neu peptide vaccine	Vaccine	—	Other
Subject	ex vivo-expanded HER2-specific T cells	Cell therapy	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	sargramostim	Protein / enzyme biologic	—	Other

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Summary

Timeline

Publications

Drugs

Indications